Hyderabad, April 26 : VINS Bioproducts Limited, a leading immunological company, based in Hyderabad, in partnership with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH) on Monday announced that it has received approval from the Drugs Controller General of India (DCGI) to commence the clinical trials for VINCOV-19, an antidote and a cure against SARS-CoV-2 virus.
VINCOV-19, a new therapeutic product, is obtained after immunization of horses with spike glycoprotein of the inactivated COVID virus. This results in the development of antibodies in the horses and the resultant antisera — the blood serum containing antibodies — is synthesised from the horse and can be injected into humans infected with Covid-19 to neutralise the virus, a company release here said.
As part of the development, VINS Bioproducts Limited selected the inactivated virus domain of the SARS-CoV-2 Spike protein as an immunogen. The results indicated that the product has a high neutralizing capacity against SARS-CoV-2.
Since neutralizing antibodies could block the internalization of SARS-CoV-2 to lung cells, it was postulated that their passive administration should render maximal clinical benefits if they are applied at early stages of the disease.(UNI)